|drug2181||No intervention, observational Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
Beyond supportive care, there are currently no proven therapeutic options for pneumonia due to coronavirus disease (COVID-19), the infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Human convalescent plasma is an option for treatment of COVID-19 and will be available when sufficient numbers of people have recovered. Such persons should have high titer neutralizing immunoglobulin-containing plasma.
Description: Identification of patient population in ICU that are in acute respiratory failure due to COVID-19 and transfuse with convalescent plasmaMeasure: Transfusion of patients in the ICU with convalescent plasma for COVID-19-induced respiratory failure. Time: Track patient progress for 28 days post initial convalescent dose.
Description: Measure reduction in ventilator use and/or changes in mechanical ventilator parametersMeasure: Ventilatory free days Time: Track patient progress for 28 days post initial convalescent dose.
Description: Measure length of stay from the time of admission to the hospital and subsequent admission to the ICU. Document resolution of COVID-19 infection or alternatively patient death.Measure: Patient mortality (including death from any cause) Time: Track patient progress for 28 days post initial convalescent dose.
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports